Drugs / XKDCT086
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT05952375 | Mar 2023 → Feb 2025 | gastric cancer | The Affiliated Hospital of Qingdao University | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XKDCT086 | “The goal of this clinical trial is to assessing the safety and tolerability of XKDCT086 cells against recurrent or refractory solid tumors with Claudin18.2 positivity.” NCT05952375 ↗ |
| Modality | Cell therapy | “the experimental drug is a chimeric antigen receptor T cell preparation targeting Claudin18.2” NCT05952375 ↗ |
| Route | Intravenous | “Medication method: intravenous drip” NCT05952375 ↗ |